Search for: [Abstract = "Results In the first analysis, a total of 114 BAVs were performed in 112 patients. The leading indication for BAV was bridge for TAVI \(n=58,51.8%\). Others included bridge for AVR \(n=6, 5.4%\), palliative treatment \(n=37, 33.0%\), cardiogenic shock \(n=2, 1.8%\), and urgent non\-cardiac surgery \(n=9, 8.0%\). To sum up, during follow\-up, 23\(20.5%\) of patients after BAV underwent TAVI and 11 \(9.8%\)patients underwent AVR. A total of 89.3% of patients were in NYHAclass III or IV. Median of STS score was 8.0 \(5.5\-10.6\)% andEuroscore II 8.1 \(5.1\-11.8\)%. Vascular closure device was used in 37\(33%\) patients. Echocardiograms performed after BAV and at 1, 6, 12months showed that AVA was higher \(\+0.23, \+0.15, \+0.05, \+0.05cm2, respectively, p<0.05 for all\) and pAVG was lower \-28.6, \-24.4, \-8.7, \-4.8 mmHg, respectively, p<0.05 for all\) as compared to baseline. In patients with impaired LV function n=34 \(30.4%, LVEF< 40%\) we observed significant improvement of LVEF \(median \+16%\) after 1 month \(p<0.05\) and this effect was stable up to 6 months after BAV. There was one severe AR after 12 months and patient was successfully treated with TAVI. Major complications occurred in 21 patients\: a\) intraprocedural death \(n=3\), b\) tamponade \(n=2\), c\) severe AR \(n=1\),d\) severe cardiac arrhythmias \(n=5\), e\) permanent pacemaker implantation \(n=1\), f\) need for red blood cells transfusion\: 1 unit in 3 patients, 2 units in 5 patients, 4 units in 4 patients, 5 units in 1 patient\(n=13\). Vascular access site complications \(VC\) occurred in 11 patients \(9.8%\). Peri\-procedural, in\-hospital, 1\-, 6\-, 12\-month mortality were 2.7%\; 8.9%\; 8.9 %\; 16.9%\; 22.3%, respectively. Inunivariate analysis females had higher prevalence of VC than males\(14.3% compared with 2.4%, p=0.04\). In multivariate logistic regression analysis, the only independent predictor of 12\-month all causemortality was STS \- HR \(95% CI\) 1.130 \(1.038 to 1.231\)\;p=0.05.In the second analysis of the 97 patients, 34 \(35.0%\) underwentstandalone BAV, 45 \(46.4%\) underwent BAV with coronary angiography and 18 \(18.6%\) BAV with PCI. Almost half of the patients who underwent BAV with PCI had a history of previous PCI.A higher contrast load, radiation dose and longer fluoroscopy time in patients with concomitant PCI or coronary angiography were noted. No higher risk of complications after BAV performed with concomitant coronary angiography\/PCI was observed. In spite of no difference in in\-hospital mortality \(5.6% vs. 8.9%\; p=0.76\), patients with BAV and concomitant PCI had lower long\-term mortality than patients with BAV and concomitant coronary angiography \(28.5% vs.51.0%\; p=0.03\). In multivariable Cox analysis adjusted for age, sex and body mass index, the STS Risk of Mortality score was identifiedas the only independent predictor of long\-term mortality for all patients \(HR 1.09, 95% CI 1.04\-1.15\; p=0.0006\).In the third analysis, balloon PD after TAVI was performed in 23\(22.8%\) patients. In 95.6%, post\-implantation PVL reduction was successful \(no or mild PVL\). PD increased ARI from 23.4% \(22.4–24.0\) to 27.1% \(26.1–28.3\)\; p < 0.001. Thirty\-day mortality rate was14.1% in the PD \(–\) group vs. 0.0% in the PD \(\+\) group\; p=0.07. One\-year mortality \(21.8% vs. 4.3%\; p=0.97\) and procedural stroke rate\(7.7% vs. 8.7%\; p=0.99\) were not different between the groups."]

Number of results: 0